1-Phenylpiperazine → N-{[4-({(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl}amino)-3-nitrophenyl]sulfonyl}-4-phenylpiperazine-1-carboxamide

HRID 1795843Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1795843
[C:1]1([N:7]2[CH2:12][CH2:11][NH:10][CH2:9][CH2:8]2)[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=1.C(N(CC)CC)C.ClC(Cl)(O[C:24](=[O:30])OC(Cl)(Cl)Cl)Cl.[CH3:32][N:33]([CH3:59])[CH2:34][CH2:35][C@@H:36]([NH:45][C:46]1[CH:51]=[CH:50][C:49]([S:52]([NH2:55])(=[O:54])=[O:53])=[CH:48][C:47]=1[N+:56]([O-:58])=[O:57])[CH2:37][S:38][C:39]1[CH:44]=[CH:43][CH:42]=[CH:41][CH:40]=1>ClCCl.CN(C1C=CN=CC=1)C>[CH3:59][N:33]([CH3:32])[CH2:34][CH2:35][C@@H:36]([NH:45][C:46]1[CH:51]=[CH:50][C:49]([S:52]([NH:55][C:24]([N:10]2[CH2:11][CH2:12][N:7]([C:1]3[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=3)[CH2:8][CH2:9]2)=[O:30])(=[O:53])=[O:54])=[CH:48][C:47]=1[N+:56]([O-:58])=[O:57])[CH2:37][S:38][C:39]1[CH:40]=[CH:41][CH:42]=[CH:43][CH:44]=1

Komponenten

7

Edukt 4

HCID 70961-PhenylpiperazineHCID 8471TriethylamineHCID 94429TriphosgeneHCID 11502754(R)-4-((4-(Dimethylamino)-1-(phenylthio)butan-2-yl)amino)-3-nitrobenzenesulfonamide

Produkt 1

HCID 10196923N-{[4-({(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl}amino)-3-nitrophenyl]sulfonyl}-4-phenylpiperazine-1-carboxamideAusbeute 41 %

Reagenzien, Katalysatoren, Lösungsmittel 2

HCID 142844-(Dimethylamino)pyridineKatalysatorHCID 6344DichloromethaneLösungsmittel

Reaktionsbedingungen

Temperatur
0 °C

Versuchsvorschrift

A solution of N-phenylpiperazine (30 mg, 0.185 mmol) in dichloromethane (2 mL) was treated with triethylamine (77 μL, 0.555 mmol), cooled to 0° C., treated with triphosgene (33 mg, 0.111 mmol), warmed to room temperature, stirred for 1 hour, treated with 4-({(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl}amino)-3-nitrobenzenesulfonamide (prepared according to the procedure described in commonly owned U.S. patent application Ser. No. 09/957,256, filed Sep. 20, 2001, 86 mg, 0.204 mmol) and DMAP (23 mg, 0.185 mmol), stirred overnight, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 20% 2N NH3 in methanol/dichloromethaneto provide the desired product (46 mg, 41%). MS (ESI) m/e 613 (M+H)+; 1H NMR (500 MHz, CD3OD) δ 8.0–6.75 (13H, m), 4.15 (1H, m), 3.59 (2H, t), 3.39 (4H, m), 3.25 (4H, m), 3.16 (2H, t), 2.88 (6H, s), 2.35–2.15 (2H, m).

Aufarbeitung

  1. temperaturewarmed to room temperature
  2. customprepared
  3. concentrationconcentrated
  4. customThe concentrate was purified by flash column chromatography on silica gel with 20% 2N NH3 in methanol/

Quellen und Nachweise

ORD-Eintrag
ord-d06e50dc9c8147acb2f897cfc96f1cb7
Quelldatensatz
uspto-grants-2006_04
Patentnummer
US07030115B2

Notizen zur Reaktion

Wird geladen…